Rezo Therapeutics,The Applied AI Company, Temedica
CatalYm Closes €50M Series C Funding
The company CatalYm announces the closing of a EUR 50 million Series C financing round. The investment was made by Brandon Capital and Jeito Capital with participation from existing investors Forbion, Novartis Venture Fund, Vesalius Biocapital III, Bayern Kapital, BioGeneration Ventures and Coparion.
The funding will be used for further clinical development of visugromab. The humanized monoclonal antibody is used to neutralize tumor-produced growth differentiation factor-15 (GDF-15). GDF-15 acts as a key regulator of immune cell activation and an inhibitor of immune cell infiltration into tumor tissue. The funding will also be used to expand the second phase of CatalYm's development program. This expansion is based on compelling efficacy and durability results in late-stage patients and the continued positive GDFATHER-2 clinical trial. Initial data from the Phase 2 clinical trial program is expected in early 2023.
https://www.vc-magazin.de/blog/2022/11/23/catalym-50-mio-series-c-finanzierung/Munich health startup Temedica collects 25 million euros
The digital health startup Temedica has raised 25 million euros as part of an extended Series B financing round. The round is led by MIG Capital and a Munich family office. The Series B round totals 42 million euros. Among other things, Temedica operates the Permea platform, which collects data from the healthcare system. This includes, for example, data from scientific publications and patient information. Permea should be able to collect, analyze and evaluate all this information. It is intended to benefit companies in the healthcare industry as well as physicians and authorities, who can use this information to make better decisions regarding patient care. The company currently has 80 employees. Gloria Seibert and Clemens Kofler founded Temedica in 2016.
Münchener Health-Startup Temedica sammelt 25 Millionen Euro ein | GS Startup-Ticker - Business Insider
Alles, was man über Startups wissen muss. Auf einen Blick. Die Kurznachrichten aus der Szene könnt ihr hier verfolgen.
The Applied AI Company Raises $42M in Funding
The Applied AI Company, a London, UK-based company that builds products for pharmaceutical, healthcare, safety and government sectors, raised $42M in funding.
The round was led by G42, A.R.M Holding, Plug and Play Investment Group as well as families in Europe and the MENA region. Seed investors included Stefan von Liechtenstein, Garry Kasparov, Dennis Mahoney, Valnon Holding, Freud Holdings, HCS GmbH, Plug and Play Investment Group, Bolur Corporation and the same A.R.M. Holding, amongst others.
The company intends to use the funds to accelerate its growth in the US and Europe
Founded in September 2021 and led by Arya Bolurfrushan, Founder and CEO, The Applied AI Company (AAICO) builds products to help automate mission critical human processes within the insurance, pharmaceutical, healthcare, safety and government sectors. Its products reduce human error, manual processes and upgrade productivity.
The engineering team is based in San Francisco, Berlin and the UAE.
https://buttondown.email/emails/85e590bb-8bfb-4cf0-a7af-08f2a1576eaeDispatchHealth Raises Over $330M in Debt and Equity Funding
DispatchHealth, a Denver, CO-based in-home medical care provider, raised over $330M in Debt and Equity funding.
The equity round of $259M was led by Optum Ventures, with participation from Adams Street Partners, Blue Shield of California, Humana, Echo Health Ventures, Questa Capital and Oak HC/FT.
The debt financing of $75M come from K2 HealthVentures, Silicon Valley Bank and SVB Capital. Up to an additional $75M is available for growth initiatives.
The company intends to use the funds to further accelerate its in-home, technology-enabled system of care.
Led by CEO Dr. Mark Prather, DispatchHealth is building an in-home system of care and offers on-demand acute care and medical care for people of all ages in the comfort of their own homes. Its emergency medicine and internal medicine trained medical teams are equipped with the tools necessary to treat common to complex injuries and illnesses. DispatchHealth works closely with payers, providers, health systems, EMS, employer groups and others to deliver care in the home to reduce unnecessary emergency room visits, hospital stays and readmissions. It is partnered with most major insurance companies.
Today, DispatchHealth provides high acuity care to complex patients across 34 states and has developed innovative relationships with health plans, provider groups, health systems, employers, senior living facilities, and home health organizations to deliver a better, more coordinated healthcare experience.
https://www.finsmes.com/2022/11/dispatchhealth-raises-over-330m-in-debt-and-equity-funding.html
Rezo Therapeutics Raises $78M in Series A Funding
Rezo Therapeutics, San Francisco, CA-based biotechnology company, raised $78M in Series A funding.
The round was led by SR One, a16z Bio + Health, and Norwest Venture Partners, and also included SV Angel, Liquid 2 Ventures, and Hawktail.
The company intends to use the funds to expand operations and its development efforts.
Led by CEO Nevan Krogan, Rezo is pursuing an integrated approach to drug discovery that leverages the multiple technologies and tools needed to bring disease networks into focus, pinpointing novel targets and therapies. Its Sequence to Systems to Drugs (SSD) platform integrates proteomics, genetics, structural biology, chemistry and bioinformatics to create maps of molecular disease networks. Based on the work of the founding team at the Quantitative Biosciences Institute (QBI) at the University of California, San Francisco (UCSF), the company’s initial focus is in oncology, with plans to explore additional therapeutic areas through collaborations and partnerships.
Chemistry inventor of drugs targeting KRAS, Kevan Shokat, Ph.D., is also a co-founder as well as a professor at UCSF, and an investigator of the Howard Hughes Medical Institute (HHMI). George Scangos, Ph.D., is co-founder and chairman of the board at Rezo
Rezo Therapeutics Raises $78M in Series A Funding
Rezo Therapeutics, San Francisco, CA-based biotechnology company, raised $78M in Series A funding
Biocare Medical Buys Empire Genomics
Biocare Medical, a San Francisco, CA-based provider of immunohistochemistry (IHC) and FISH, acquired Empire Genomics, a Buffalo, NY-based provider of molecular biomarkers.
The amount of the deal was undisclosed.
Together, Biocare Medical and Empire Genomics will bring an expanded offering of solutions to those researching and diagnosing cancer around the world.
Empire Genomics is a provider of FISH and ISH, offering over one million biomarkers. These biomarkers enable research and clinical institutions to bring clinically relevant tests. The company enables research to transform into impactful clinical and research tools worldwide. The comprehensive product portfolio includes Fluorescence in situ Hybridization (FISH) and Chromogenic in situ Hybridization (CISH) probes designed and optimized for specific diseases, genes, or regions across the entire human and mouse genomes.
Led by CEO Luis de Luzuriaga, Biocare Medical is a provider of solutions for cancer research and diagnostics, providing: reagents, including tissue-conserving simultaneous Multiplex IHC antibody cocktails and detections; Customer Care; and a comprehensive suite of instrumentation for IHC, molecular, and histology testing. Its reagent portfolio includes primary antibodies, Multiplex IHC, and FISH probes for target indications. Biocare also offers a line of polymer detections for clinical, human, and animal research that deliver high sensitivity and exceptionally low background. The company’s automated instrument platforms, intelliPATH and ONCORE Pro, have been designed to meet every need from high throughput clinical diagnostics to flexible research requirements.
Customers include clinical anatomic pathology laboratories, pharmaceutical companies, CROs, and biotechnology companies as well as academic, government, military, and other non-profit laboratories.
Biocare Medical Buys Empire Genomics - FinSMEs
Biocare Medical, a San Francisco, CA-based provider of immunohistochemistry (IHC) and FISH, acquired Empire Genomics, a Buffalo, NY-based provider of molecular biomarkers
Scanmed Acquires Ars Medical
Scanmed, a Warsaw, Poland-based healthcare company, acquired Ars Medical, another Polish cancer care treatment company.
The amount of the deal, supported by Abris Capital Partners, was not disclosed.
With the acquisition, Scanmed will become the largest independent healthcare provider in Poland. The deal will broaden Scanmed’s offer to accommodate the needs of its clients and will strengthen its position as a private in-patient healthcare provider. Additionally, the acquisition will enable synergies with existing Scanmed facilities and expand the company’s presence in north-west Poland.
Led by CEO Dr Zygmunt Malinowski, Ars Medical specialises in oncology, haematology, cardiology, internal medicine and palliative care, as well as general and specialist outpatient care. The company is a local players in cancer care treatment, diagnostic imaging and commercial procedures, and has a team of 400 doctors and nurses, including over 100 specialists in 48 therapeutic areas.
Led by CEO Andrzej Podlipski, Scanmed is a healthcare provider in Poland, offering a wide range of medical services within primary care, outpatient specialist consultations, diagnostics and inpatient/hospital treatment. Scanmed Group offers its patients an access to comprehensive therapeutic methods, technologically advanced and medical equipment and experienced specialists to facilitate their recovery.
Abris acquired Scanmed in 2020 with a plan to build a local healthcare champion by improving and growing the group’s service offering in key therapeutic areas including cardiology, oncology, orthopedics and ophthalmology, and expand its countrywide geographic coverage.